Massachusetts Medical Society

Recent papers from Massachusetts Medical Society

1. AMETHYST : a Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid‐refractory Macrophage Activation Syndrome Complicating Still's DiseaseArthritis & Rheumatology · 2026
2. Variations in the Management of Uncontrolled Gout Between Rheumatologists and Nephrologists: A Retrospective Medical Record ReviewACR Open Rheumatology · 2026
3. Development of a Disease Activity Index for the Assessment of VEXAS Syndrome ( VEXAS ‐ DAI )Arthritis Care & Research · 2026
4. Avatrombopag in thrombopoietin receptor agonist-naïve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 studyResearch and Practice in Thrombosis and Haemostasis · 2026
5. Medical ozone: mechanisms, biological effects and clinical evidence—a narrative reviewFrontiers in Medicine · 2026
6. Analytical comparison of physiological parameters in participants during an analog space missionFrontiers in Space Technologies · 2026
7. CD8 PET imaging with [ ⁸⁹ Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyJournal for ImmunoTherapy of Cancer · 2026
8. PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS SyndromeJournal of Clinical Medicine · 2026
9. Etiology of autism spectrum disorders: recent advances and emerging directionsCurrent Opinion in Psychiatry · 2026
10. Bridging the Artificial Intelligence (AI) Gap: A Knowledge, Attitude, and Practice (KAP) Study to Advance Medical Education in Rural Andhra PradeshCureus · 2025
11. TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular DegenerationOphthalmology Retina · 2025
12. Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesClinical Cancer Research · 2025
13. AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid TumorsClinical Cancer Research · 2025
14. Focal point technology: Controlling treatment depth and pattern of skin injury by a novel highly focused laserJournal of the American Academy of Dermatology · 2024
15. How To Measure Benefit in a Changing Pandemic — Olgotrelvir for SARS-CoV-2NEJM Evidence · 2024
16. A Last Hurrah: Reply to Sharif et al Regarding ChinaTransplantation · 2024
17. Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled TrialsClinical Neuropharmacology · 2024
18. Blood pressure response to extended-release naltrexone in heroin and prescription opioid users and its implications for cardiovascular morbidityJournal of Addictive Diseases · 2024
19. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational BurdenClinical Cancer Research · 2023
20. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform TrialCancer Discovery · 2023